Corticotropin is under clinical development by Mallinckrodt and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Corticotropin’s likelihood of approval (LoA) and phase transition for IgA Nephropathy (Berger’s Disease) took place on 20 Dec 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Corticotropin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Corticotropin, Repository Corticotropin (H.P. Acthar/Acthar) is a purified preparation of the adrenocorticotropic hormone (ACTH) obtained from porcine pituitary. It is formulated as injection gel for intramuscular and subcutaneous route of administration and powder for solution for intravenous, intramuscular and subcutaneous routes of administration. It is indicated for the treatment of infantile spasms, multiple sclerosis (acute exacerbations of multiple sclerosis), rheumatic disorders (Psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis, ankylosing spondylitis), collagen diseases (systemic lupus erythematosus, systemic dermatomyositis (polymyositis)), dermatologic diseases (severe erythema multiforme, Stevens-Johnson syndrome), allergic states (Serum sickness), ophthalmic diseases (keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation), respiratory diseases (pulmonary sarcoidosis) and edematous states (proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus). In the treatment of infantile spasms, H.P. Acthar Gel must be administered intramuscularly.
It is under development for the treatment of IgA nephropathy.
The drug candidate was under development for the treatment of amyotrophic lateral sclerosis. It was also under development for the treatment of acute respiratory syndrome, chronic migraine, diabetic nephropathy, and proteinuria.
Mallinckrodt develops, produces, markets, and distributes specialty pharmaceutical products and therapies. The company offers branded pharmaceutical products for autoimmune and rare diseases in specialty areas such as rheumatology, nephrology, neurology, pulmonology and ophthalmology. It also offers immunotherapy, oncology and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company offers specialty generic drugs and active pharmaceutical ingredients. Mallinckrodt markets branded products directly to physicians, specialty pharmacies, hospitals and ambulatory surgical centers; and also distributes branded and generic products through a network of drug distributors, specialty pharmaceutical distributors and retail pharmacy chains, among others. It has facilities in the US, Ireland, Japan and other countries. Mallinckrodt is headquartered in Dublin, Ireland.
Quick View Corticotropin LOA Data
|Highest Development Stage|